Triple therapy shows promise for advanced liver cancer
NCT ID NCT05332821
First seen Apr 17, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tested a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), immunotherapy (PD-1/PD-L1 inhibitors), and targeted drugs (VEGF-TKI or bevacizumab)—in over 1,200 people with advanced liver cancer that had spread. The goal was to see if this triple therapy could help people live longer and slow cancer growth. Participants had not received any prior systemic treatment for their liver cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gao-Jun Teng
Nanjing, China
-
Zheng-Gang Ren
Shanghai, China
Conditions
Explore the condition pages connected to this study.